Company Overview and News

0
More Boardroom Diversity Means Less in C-Suite, Lucara CEO Says - Bloomberg

2018-06-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LUC LUCRF

177
CANADA STOCKS - TSX rises 0.42 pct as energy climbs

2018-06-18 reuters
NEW YORK, June 18 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 69.21 points, or 0.42 percent, to 16,383.63. * The biggest contributor to the TSX gain was TransCanada , while the top sector contributor was energy. * Leading the index were Canada Goose Holdings Inc, up 9.8 percent, Bombardier Inc, up 6.4 percent, and Lucara Diamond Corp , higher by 6.1 percent. * Lagging shares were Baytex Energy Corp, down 12.
LUC GOOS LUCRF BDRPF VRX RRENF BTE RRX

6
Orca Gold Inc. Announces Annual General Meeting Results and New Chief Financial Officer

2018-06-01 globenewswire
VANCOUVER, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Orca Gold Inc. (TSXV:ORG) (“Orca” or the “Company”) is pleased to announce that the nominees set forth in the Company’s management information circular dated April 26, 2018, L. Simon Jackson, Richard Clark, Hugh Stuart, Alexander Davidson, Robert Chase, David Field and Derek White were elected as directors of the Company at the Annual General Meeting held on May 30, 2018 (the “Meeting”).
LUC LUCRF AAUKF AAL CANWF ORG NGLOY

0
Lucara Announces Declaration of Quarterly Dividend

2018-05-09 globenewswire
VANCOUVER, BRITISH COLUMBIA, May 08, 2018 (GLOBE NEWSWIRE) -- Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC)(BOTSWANA:LUC)(NASDAQ OMX Stockholm:LUC) is pleased to announce that the Board of Directors has declared the second 2018 quarterly dividend of CDN 2.5 cents per share to be payable Thursday, June 21, 2018 to the shareholders of record at the close of business on Friday, June 8, 2018.
LUC LUCRF

0
Lucara Announces First Quarter 2018 Results

2018-05-08 globenewswire
Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC)(BOTSWANA:LUC)(NASDAQ OMX Stockholm:LUC) is pleased to announce results for the three months ended March 31, 2018.
LUC LUCRF

0
Lucara Announces Appointment of Managing Director, Boteti Botswana

2018-05-01 globenewswire
(LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. (“Lucara” or the “Company”) is pleased to announce the promotion of Naseem Lahri, BCOM, FCCA to Managing Director of Boteti Mining (Pty) Ltd, Lucara’s 100% owned subsidiary in Botswana, effective immediately.
LUC LUCRF

0
LUCARA 2018 FIRST QUARTER RESULTS TO BE RELEASED TUESDAY, MAY 8, 2018

2018-04-19 globenewswire
VANCOUVER, BRITISH COLUMBIA, April 19, 2018 (GLOBE NEWSWIRE) -- Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC) (BOTSWANA:LUC) (NASDAQ OMX Stockholm:LUC) announces that it will be publishing its 2018 First Quarter results on Tuesday, May 8, 2018, after the market close in North America.
LUC LUCRF

0
Lucara 2018 First Quarter Results to Be Released Tuesday, May 8, 2018

2018-04-19 globenewswire
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC) (BOTSWANA:LUC) (NASDAQ OMX Stockholm:LUC) announces that it will be publishing its 2018 First Quarter results on Tuesday, May 8, 2018, after the market close in North America.
LUC LUCRF

0
Lucara Unearths Another Massive Diamond From Botswana Mine - Bloomberg

2018-04-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LUC LUCRF

0
Lucara Annual General Meeting to Be Held May 10, 2018

2018-04-10 globenewswire
VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) -- Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC) (BOTSWANA:LUC) (NASDAQ OMX Stockholm:LUC) announces that its Annual General Meeting of Shareholders will be held at Suite 2600, Pacific Boardroom, 595 Burrard Street, Vancouver, British Columbia, V7X 1L3 on Thursday, May 10, 2018, at 10:00 a.m. (Pacific Daylight Time), for the following purposes:
LUC LUCRF

0
LUCARA ANNUAL GENERAL MEETING TO BE HELD MAY 10, 2018

2018-04-10 globenewswire
(LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. ("Lucara" or the "Company") announces that its Annual General Meeting of Shareholders will be held at Suite 2600, Pacific Boardroom, 595 Burrard Street, Vancouver, British Columbia, V7X 1L3 on Thursday, May 10, 2018, at 10:00 a.m. (Pacific Standard Time), for the following purposes:
LUC LUCRF

0
Pangolin Signs Agreement to Acquire Ownership in AK10, a 6 Hectare Diamondiferous Kimberlite Pipe, Botswana Africa

2018-04-03 globenewswire
TORONTO, April 03, 2018 (GLOBE NEWSWIRE) -- Pangolin Diamonds Corp. (TSX-V:PAN) (the "Company" or "Pangolin") is pleased to announce it has signed an option agreement (the “Agreement”) with Makanwu Civil Blasting (PTY) Ltd. (“MCB”), a private company incorporated under the laws of the Republic of Botswana. Under the Agreement, MCB has granted Pangolin the sole and exclusive option to earn up to a 75% interest in respect of MCB’s precious stone AK10 Diamond Project located in the Central District of Botswana, Africa.
LUC PAN LUCRF FDI KGHZF

0
Lucara Share Capital and Voting Rights Update

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 29, 2018 (GLOBE NEWSWIRE) -- Lucara Diamond Corp. ("Lucara" or the "Company") (TSX:LUC) (BOTSWANA:LUC) (NASDAQ OMX Stockholm:LUC) reports the following in accordance with the Swedish Financial Instruments Trading Act:
LUC LUCRF

0
LUCARA SHARE CAPITAL AND VOTING RIGHTS UPDATE

2018-03-29 globenewswire
Vancouver, March 29, 2018 (GLOBE NEWSWIRE) -- (LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. ("Lucara" or the "Company") reports the following in accordance with the Swedish Financial Instruments Trading Act:
LUC LUCRF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 54928Q108